Literature DB >> 18537688

Recent advances in liver X receptor biology and chemistry.

Bryan J Goodwin1, William J Zuercher, Jon L Collins.   

Abstract

The liver X receptors LXR alpha and LXR beta are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. Seminal studies with genetic and chemical tools were instrumental in the elucidation of cholesterol metabolism, gluconeogenesis, inflammation, and lipogenesis as signaling pathways that are controlled by the LXRs. First generation non-steroidal LXR agonists show beneficial effects in multiple animals models of human disease yet have not progressed in the clinic due to deleterious side effects in the liver. Numerous reports have appeared in the the recent literature that disclose new LXR signaling pathways and the identification of novel LXR chemotypes that may show improved therapeutic indices. This review will provide a brief historical perspective but will primarily focus on recent advances in LXR biology and chemistry.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537688     DOI: 10.2174/156802608784535075

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  8 in total

Review 1.  The glycerophosphoinositols: cellular metabolism and biological functions.

Authors:  Daniela Corda; Pasquale Zizza; Alessia Varone; Beatrice Maria Filippi; Stefania Mariggiò
Journal:  Cell Mol Life Sci       Date:  2009-08-09       Impact factor: 9.261

2.  Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis.

Authors:  Spyridon Theofilopoulos; Yuqin Wang; Satish Srinivas Kitambi; Paola Sacchetti; Kyle M Sousa; Karl Bodin; Jayne Kirk; Carmen Saltó; Magnus Gustafsson; Enrique M Toledo; Kersti Karu; Jan-Åke Gustafsson; Knut R Steffensen; Patrik Ernfors; Jan Sjövall; William J Griffiths; Ernest Arenas
Journal:  Nat Chem Biol       Date:  2012-12-23       Impact factor: 15.040

3.  LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse.

Authors:  Elaine M Quinet; Michael D Basso; Anita R Halpern; David W Yates; Robert J Steffan; Valerie Clerin; Christine Resmini; James C Keith; Thomas J Berrodin; Irene Feingold; Wenyan Zhong; Helen B Hartman; Mark J Evans; Stephen J Gardell; Elizabeth DiBlasio-Smith; William M Mounts; Edward R LaVallie; Jay Wrobel; Ponnal Nambi; George P Vlasuk
Journal:  J Lipid Res       Date:  2009-03-24       Impact factor: 5.922

4.  Effects of FoxO4 overexpression on cholesterol biosynthesis, triacylglycerol accumulation, and glucose uptake.

Authors:  Jun Zhu; Khalid Mounzih; Eric F Chehab; Nico Mitro; Enrique Saez; Farid F Chehab
Journal:  J Lipid Res       Date:  2009-12-25       Impact factor: 5.922

5.  Identification of novel liver X receptor activators by structure-based modeling.

Authors:  Susanne von Grafenstein; Judit Mihaly-Bison; Gerhard Wolber; Valery N Bochkov; Klaus R Liedl; Daniela Schuster
Journal:  J Chem Inf Model       Date:  2012-04-20       Impact factor: 4.956

6.  LXRα promotes cell metastasis by regulating the NLRP3 inflammasome in renal cell carcinoma.

Authors:  KeShan Wang; TianBo Xu; HaiLong Ruan; HaiBing Xiao; Jingchong Liu; ZhengShuai Song; Qi Cao; Lin Bao; Di Liu; Cheng Wang; Gong Cheng; HuaGeng Liang; ZhaoHui Chen; HongMei Yang; Ke Chen; XiaoPing Zhang
Journal:  Cell Death Dis       Date:  2019-02-15       Impact factor: 8.469

7.  Regulation of bile acid and cholesterol metabolism by PPARs.

Authors:  Tiangang Li; John Y L Chiang
Journal:  PPAR Res       Date:  2009-07-14       Impact factor: 4.964

Review 8.  Natural Products Targeting Liver X Receptors or Farnesoid X Receptor.

Authors:  Jianglian She; Tanwei Gu; Xiaoyan Pang; Yonghong Liu; Lan Tang; Xuefeng Zhou
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.